
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated a robust performance, highlighted by an 11% sequential increase in gross business awards, driven by successful partnerships with both biotech and large pharmaceutical customers. The company has not only met or exceeded its financial targets following the PRA acquisition but also benefits from a favorable client mix, positioning it well against potential funding challenges. Additionally, as the market for contract research organizations (CRO) continues to grow, Icon is poised to enhance its clinical trial research capabilities, further solidifying its competitive advantage.
Bears say
The analysis indicates a concerning trend in Icon's financial performance, particularly with projected EBITDA margins for 2024 and 2025 now expected to be in the high-19% range, slightly lower than previous expectations of around 20%. Additionally, potential downside risks include a slowdown in clinical trial activity due to pharma reprioritizations, uncertainties in biotech funding, and issues related to the inability to realize revenue synergies from the PRA transaction. Furthermore, external factors such as inflation and a slowdown in pharmaceutical R&D spending pose significant threats to Icon's overall revenue growth and profitability, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares